Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025

Vinge advises on the sale of Kaelus to Baylin Technologies

Baylin Technologies, listed on the Toronto Stock Exchange, has entered into an agreement to acquire all shares in the Swedish company, Kaelus for approximately SEK 285 million with the aim of creating a global leader in wireless technology.
December 01, 2025

Vinge advises in connection with data center provider EcoDataCenter’s issue of SEK 500 million senior unsecured bonds

Vinge has advised ABG Sundal Collier in connection with EcoDC Holding AB (publ)'s issue of SEK 500 million senior unsecured bonds, within a framework of up to SEK 2 billion.
November 28, 2025